Biotech Companies Focused On Cancer Research Are Being Acquired At Massive Valuations

FN Media Group Presents USA News Group News Commentary


Los Angeles, CA  – November 20, 2019 – USA News Group –  The global biotech market will surpass $775 billion USD by 2024; according to a new research report by Global Market Insights, Inc.     The industry is one of the most exciting sectors to follow, acting as a strong engine of innovation, a source of highly skilled employment, and destination for investment capital.   Mentioned in today’s commentary includes:  Seattle Genetics (NASDAQ: SGEN), Karuna Therapeutics (NASDAQ: KRTX), Bristol-Myers Squibb (NYSE: BMY), Pfizer (NYSE: PFE),  Oncolytics Biotech (NASDAQ: ONCY).


This opinion is echoed by portfolio managers who think the industry has plenty of room to run. As more useful IP is developed by some of the top players, newcomers are also making a dent, positioning themselves for further M&A’s which are rising in popularity year over year.


The biotech industry contains well known companies looking to develop the industry’s top IP such as Seattle Genetics (NASDAQ: SGEN) who began 2019 with big news about its flagship Adcetris product.


Innovative companies like Karuna Therapeutics (NASDAQ: KRTX) topped headlines recently when it announced their KarXT had met primary endpoint in Phase 2 clinical trial of acute Psychosis in patients with Schizophrenia, and the stock has more than tripled in less than 2 days since the announcement. Bristol-Myers Squibb (NYSE: BMY) recently announced they had received clearance from U.S. Federal Trade Commission for Celgene Acquisition.


What Is the Large Scale Outlook Here?


Biotech continues to grow at a rapid pace, so it makes sense then that the industry would be attracting all kinds of new investors to both the industry giants, and small-mid cap companies alike.


Like most industries, biotech suffered losses toward the end of 2018 along with the broader stock market. However, 2019 has proven to be a very positive year for the sector as a whole with most stocks making large moves.


Ivo Staijen, manager of the HBM Global Biotechnology fund, is also feeling optimistic about the sector’s prospects, pointing out the number of constituents in the Nasdaq Biotechnology index has increased sharply in recent years.


‘Most investors have exposure to the large pharmaceutical giants but from a value creation perspective they should be invested in earlier-stage companies too. Biotechnology is the backbone of innovation these days,’ says Staijen


Others prefer to back giants like Pfizer (NYSE: PFE), whose portfolio focuses on the discovery and development of new medicines and vaccines. By focusing on science and patient experience, they have significant investments which support faster delivery of breakthrough medicines. Pzizer is also growing through M&A, a very well known move within the sector. The company announced its $11.4 billion USD plan to acquire Array BioPharma.


Start With IP


The IP that drives biotech may be one of the easy entry points for early investors to look at. Oncolytics Biotech developed tech known as Pelareorep, a non-pathogenic, proprietary treatment for cancerous tumors. It’s unlike any other treatment on the market, and  the company is looking to enter phase 3 testing come 2020.


Pelareorep selectively replicates in permissive cancer cells. Upon virus replication, cancer cells die, releasing additional virus particles to infect nearby cancer cells. This is a unique treatment within the sector.


The company has also begun to work with industry giant Pfizer (NYSE: PFE) to develop IP through new studies. Oncolytics Biotech (NASDAQ: ONCY) will be developing programs to evaluate the efficacy and safety in their clinical studies targeting early stage breast cancer, multiple myeloma and other various hard to target cancers.


Going In On Niche Market Segments


Oncolytics Biotech (NASDAQ: ONCY) originally hails from Canada, but has operations in San Diego as well, and the company is listed on the TSX and NASDAQ exchanges.


If cancer biotech can reach the kind of massive revenue numbers the current data suggests, some of these newcomers may become the future giants of the industry that come to define the future of biotech, medical research and pharmaceutical IP. Along with Oncolytics, three other companies also seeking to take an active lead in this sector include:


Seattle Genetics (NASDAQ: SGEN) who generated one of the most impressive stock performances among biotechs for 2019. The Seattle based company creates and markets cancer treatment drugs and has become known as the industry leader in antibody-drug conjugates.


Alexion is a Boston based biotech company, and the maker of Soliris, a drug used to treat multiple rare disorders affecting the body. Alexion remains heavily involved in immune system research as it relates to autoimmune diseases.


Incyte is a pharmaceutical company based out of Delaware. The company focuses on drug treatments for cancer, arthritis and other diseases. Their most famous drug available to consumers is called Jakafi, which is used to treat polycythemia vera. The company began 2019 with a phase 3 trial of new medicine. The company announced that the first patient had been treated with Itacitinib as part of the trial midway through the month.


For more on Oncolytics Biotech and the broader biotech industry, view the report at USA News Group:


Article Source:

USA News Group


Legal Disclaimer/Disclosure:


This piece is an advertorial and has been paid for. This document is not and should not be construed as an offer to sell or the solicitation of an offer to purchase or subscribe for any investment. No information in this Report should be construed as individualized investment advice. A licensed financial advisor should be consulted prior to making any investment decision. We make no guarantee, representation or warranty and accept no responsibility or liability as to its accuracy or completeness. Expressions of opinion are those of USA News Group only and are subject to change without notice. USA News Group assumes no warranty, liability or guarantee for the current relevance, correctness or completeness of any information provided within this Report and will not be held liable for the consequence of reliance upon any opinion or statement contained herein or any omission. Furthermore, we assume no liability for any direct or indirect loss or damage or, in particular, for lost profit, which you may incur as a result of the use and existence of the information, provided within this Report.


DISCLAIMER:  USA News Group is Source of all content listed above.  FN Media Group, LLC (FNM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with USA News Group or any company mentioned herein.  The commentary, views and opinions expressed in this release by USA News Group are solely those of USA News Group and are not shared by and do not reflect in any manner the views or opinions of FNM.  FNM is not liable for any investment decisions by its readers or subscribers.  FNM and its affiliated companies are a news dissemination and financial marketing solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security.  FNM was not compensated by any public company mentioned herein to disseminate this press release.




This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.

Media Contact Information:
FN Media Group, LLC
Media Contact e-mail:
U.S. Phone: +1(954)345-0611